Cheng-Wei Liu1, Pen-Chih Liao2, Kuo-Chin Chen2, Jung-Cheng Hsu3, Ai-Hsien Li2, Chung-Ming Tu3, Yen-Wen Wu4. 1. Cardiology Division of Cardiovascular Medical Center, Far Eastern Memorial Hospital, New Taipei City; ; Department of Internal Medicine, Tri-Service General Hospital, Songshan Branch; ; National Defense Medical Center. 2. Cardiology Division of Cardiovascular Medical Center, Far Eastern Memorial Hospital, New Taipei City. 3. Cardiology Division of Cardiovascular Medical Center, Far Eastern Memorial Hospital, New Taipei City; ; Chihlee Institute of Technology. 4. Cardiology Division of Cardiovascular Medical Center, Far Eastern Memorial Hospital, New Taipei City; ; Departments of Internal Medicine; ; Departments of Nuclear Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei; ; Department of Nuclear Medicine, Far Eastern Memorial Hospital, New Taipei City; ; National Yang-Ming University School of Medicine, Taipei, Taiwan.
Abstract
BACKGROUND: The association between hemoglobin (Hb) levels and mortality in patients with ST-segment elevation myocardial infarction (STEMI) remains controversial. The purpose of this study was to examine the mortality among STEMI patients with anemia or erythrocytosis, and further establish the relationship between mortality and the increment of Hb level. METHODS: Between 2006 and 2012, 951 consecutive patients with STEMI undergoing primary percutaneous coronary intervention in a medical center in Northern Taiwan were enrolled in our study, including 535 patients with normal Hb level, 148 with anemia (male Hb ≤ 13 g/dl, female ≤ 12) and 268 with erythrocytosis (male Hb ≥ 16, female ≥ 15). RESULTS: Patients in the anemia group were the oldest, and had higher morbidity than the normal Hb group, followed by the erythrocytosis group. In regression analyses, neither anemia nor erythrocytosis was associated with 30-day and 1-year mortality. Each 1-g/dl increment of Hb level was not associated with 30-day mortality both in patients with anemia or erythrocytosis. However, it was associated with a decreased risk of 1-year mortality in anemic patients [hazard ratio (HR): 0.756, 95% confidence interval (CI): 0.608-0.938, p = 0.011] and an increased risk of 1-year mortality in those with erythrocytosis (HR: 2.086, 95%CI: 1.106-3.937, p = 0.023). In multivariate analysis, each 1-g/dl increment of Hb level was associated with 1-year mortality both in anemic patients and those with erythrocytosis (HR: 0.788, 95%CI: 0.621-0.999, p = 0.049; HR: 2.302, 95%CI: 1.051-5.04, p = 0.037). CONCLUSIONS: Higher hemoglobin levels in STEMI patients with anemia were associated with decreased risks of 1-year mortality, whereas higher hemoglobin levels in those with erythrocytosis were associated with increased risks of one-year mortality.
BACKGROUND: The association between hemoglobin (Hb) levels and mortality in patients with ST-segment elevation myocardial infarction (STEMI) remains controversial. The purpose of this study was to examine the mortality among STEMI patients with anemia or erythrocytosis, and further establish the relationship between mortality and the increment of Hb level. METHODS: Between 2006 and 2012, 951 consecutive patients with STEMI undergoing primary percutaneous coronary intervention in a medical center in Northern Taiwan were enrolled in our study, including 535 patients with normal Hb level, 148 with anemia (male Hb ≤ 13 g/dl, female ≤ 12) and 268 with erythrocytosis (male Hb ≥ 16, female ≥ 15). RESULTS:Patients in the anemia group were the oldest, and had higher morbidity than the normal Hb group, followed by the erythrocytosis group. In regression analyses, neither anemia nor erythrocytosis was associated with 30-day and 1-year mortality. Each 1-g/dl increment of Hb level was not associated with 30-day mortality both in patients with anemia or erythrocytosis. However, it was associated with a decreased risk of 1-year mortality in anemicpatients [hazard ratio (HR): 0.756, 95% confidence interval (CI): 0.608-0.938, p = 0.011] and an increased risk of 1-year mortality in those with erythrocytosis (HR: 2.086, 95%CI: 1.106-3.937, p = 0.023). In multivariate analysis, each 1-g/dl increment of Hb level was associated with 1-year mortality both in anemicpatients and those with erythrocytosis (HR: 0.788, 95%CI: 0.621-0.999, p = 0.049; HR: 2.302, 95%CI: 1.051-5.04, p = 0.037). CONCLUSIONS: Higher hemoglobin levels in STEMI patients with anemia were associated with decreased risks of 1-year mortality, whereas higher hemoglobin levels in those with erythrocytosis were associated with increased risks of one-year mortality.
Authors: Kenichi Tsujita; Eugenia Nikolsky; Alexandra J Lansky; George Dangas; Martin Fahy; Bruce R Brodie; Dariusz Dudek; Martin Möckel; Andrzej Ochala; Roxana Mehran; Gregg W Stone Journal: Am J Cardiol Date: 2010-04-02 Impact factor: 2.778
Authors: Alan S Go; Jingrong Yang; Lynn M Ackerson; Krista Lepper; Sean Robbins; Barry M Massie; Michael G Shlipak Journal: Circulation Date: 2006-06-05 Impact factor: 29.690
Authors: Tammy M Keough-Ryan; Bryce A Kiberd; Christine S Dipchand; Jafna L Cox; Caren L Rose; Kara J Thompson; Catherine M Clase Journal: Am J Kidney Dis Date: 2005-11 Impact factor: 8.860
Authors: Tomasz Kurek; Radosław Lenarczyk; Jacek Kowalczyk; Andrzej Swiatkowski; Oskar Kowalski; Joanna Stabryła-Deska; Grzegorz Honisz; Andrzej Lekston; Zbigniew Kalarus; Tomasz Kukulski Journal: Am J Cardiol Date: 2010-03-01 Impact factor: 2.778
Authors: Vijay Kunadian; Roxana Mehran; A Michael Lincoff; Frederick Feit; Steven V Manoukian; Martial Hamon; David A Cox; George D Dangas; Gregg W Stone Journal: Am J Cardiol Date: 2014-09-28 Impact factor: 2.778
Authors: Eugenia Nikolsky; Eve D Aymong; Amir Halkin; Cindy L Grines; David A Cox; Eulogio Garcia; Roxana Mehran; James E Tcheng; John J Griffin; Giulio Guagliumi; Thomas Stuckey; Mark Turco; David A Cohen; Manuela Negoita; Alexandra J Lansky; Gregg W Stone Journal: J Am Coll Cardiol Date: 2004-08-04 Impact factor: 24.094